Qilian Group (QLI) Revenue & Revenue Breakdown
Qilian Group Revenue Highlights
Latest Revenue (Y)
$46.47M
Latest Revenue (Q)
$17.31M
Main Segment (Y)
Oxytetracycline & Licorice products and TCMD
Qilian Group Revenue by Period
Qilian Group Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $46.47M | -28.35% |
| 2022-09-30 | $64.86M | 13.58% |
| 2021-09-30 | $57.10M | 14.12% |
| 2020-09-30 | $50.03M | 8.54% |
| 2019-09-30 | $46.10M | -8.48% |
| 2018-09-30 | $50.37M | 123.49% |
| 2017-09-30 | $22.54M | - |
Qilian Group generated $46.47M in revenue during NA 2023, up -28.35% compared to the previous quarter, and up 92.26% compared to the same period a year ago.
Qilian Group Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2023-09-30 | $17.31M | -40.65% |
| 2023-03-31 | $29.16M | 100.00% |
| 2022-12-31 | $14.58M | -55.50% |
| 2022-09-30 | $32.77M | 100.00% |
| 2022-06-30 | $16.38M | -48.94% |
| 2022-03-31 | $32.09M | 100.00% |
| 2021-12-31 | $16.04M | -40.93% |
| 2021-09-30 | $27.16M | 100.00% |
| 2021-06-30 | $13.58M | -54.64% |
| 2021-03-31 | $29.94M | 100.00% |
| 2020-12-31 | $14.97M | 34.41% |
| 2020-09-30 | $11.14M | - |
| 2020-06-30 | $11.14M | -19.76% |
| 2020-03-31 | $13.88M | - |
| 2019-12-31 | $13.88M | 46.59% |
| 2019-09-30 | $9.47M | - |
| 2019-06-30 | $9.47M | -30.28% |
| 2019-03-31 | $13.58M | - |
| 2018-12-31 | $13.58M | 7.33% |
| 2018-09-30 | $12.65M | - |
| 2018-06-30 | $12.65M | 0.96% |
| 2018-03-31 | $12.53M | - |
| 2017-12-31 | $12.53M | - |
Qilian Group generated $17.31M in revenue during Q4 2023, up -40.65% compared to the previous quarter, and up 53.94% compared to the same period a year ago.
Qilian Group Revenue Breakdown
Qilian Group Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Sep 23 | Sep 22 | Sep 21 |
|---|---|---|---|
| Oxytetracycline & Licorice products and TCMD | $29.15M | $40.31M | $33.45M |
| Fertilizer | $2.00M | $1.09M | $486.17K |
| Heparin products and Sausage casing | $16.27M | $23.46M | $23.16M |
| International Markets | - | - | - |
Qilian Group's latest annual revenue breakdown by segment (product or service), as of Sep 23: Oxytetracycline & Licorice products and TCMD (61.48%), Heparin products and Sausage casing (34.30%), and Fertilizer (4.22%).
Qilian Group Revenue Breakdown by Country
Annual Revenue by Country
| Country | Sep 23 |
|---|---|
| International Markets | - |
Qilian Group Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| PAHC | Phibro Animal Health | $977.89M | $263.22M |
| COLL | Collegium Pharmaceutical | $566.77M | $144.92M |
| ANIP | ANI Pharmaceuticals | $486.82M | $138.04M |
| PROC | Procaps Group | $409.92M | $118.41M |
| EGRX | Eagle Pharmaceuticals | $316.61M | $64.65M |
| AQST | Aquestive Therapeutics | $50.58M | $20.10M |
| QLI | Qilian Group | $46.47M | $17.31M |
| SSIC | Silver Spike Investment | $11.72M | $2.76B |
| JUPW | Safety Shot | $6.20M | $910.01K |
| PRFX | PainReform | - | - |
| RGC | Regencell Bioscience | - | - |
QLI Revenue FAQ
What is Qilian Group’s yearly revenue?
Qilian Group's yearly revenue for 2023 was $46.47M, representing a decrease of -28.35% compared to 2022. The company's yearly revenue for 2022 was $64.86M, representing an increase of 13.58% compared to 2021. QLI's yearly revenue for 2021 was $57.1M, representing an increase of 14.12% compared to 2020.
What is Qilian Group’s quarterly revenue?
Qilian Group's quarterly revenue for Q4 2023 was $17.31M, a -40.65% decrease from the previous quarter (Q2 2023), and a 5.64% increase year-over-year (Q3 2022). The company's quarterly revenue for Q2 2023 was $29.16M, a 100.00% increase from the previous quarter (Q1 2023), and a -9.11% decrease year-over-year (Q2 2022). QLI's quarterly revenue for Q1 2023 was $14.58M, a -55.50% decrease from the previous quarter (Q4 2022), and a -9.11% decrease year-over-year (Q1 2022).
What is Qilian Group’s revenue growth rate?
Qilian Group's revenue growth rate for the last 3 years (2021-2023) was -18.61%, and for the last 5 years (2019-2023) was 0.81%.
What are Qilian Group’s revenue streams?
Qilian Group's revenue streams in p 23 are Oxytetracycline & Licorice products and TCMD, Fertilizer, and Heparin products and Sausage casing. Oxytetracycline & Licorice products and TCMD generated $29.15M in revenue, accounting 61.48% of the company's total revenue, down -27.67% year-over-year. Fertilizer generated $2M in revenue, accounting 4.22% of the company's total revenue, up 83.77% year-over-year. Heparin products and Sausage casing generated $16.27M in revenue, accounting 34.30% of the company's total revenue, down -30.66% year-over-year.
What is Qilian Group’s main source of revenue?
For the fiscal year ending Sep 23, the largest source of revenue of Qilian Group was Oxytetracycline & Licorice products and TCMD. This segment made a revenue of $29.15M, representing 61.48% of the company's total revenue.